Status:
RECRUITING
Sleep Disorders and Tumor Immune Microenvironment
Lead Sponsor:
Shanghai Zhongshan Hospital
Conditions:
Impact of Sleep Disorders on Tumor Immune Microenvironment and Clinical Outcomes in Lung Cancer
Eligibility:
All Genders
18-70 years
Brief Summary
Title: Impact of Sleep Disorders on Tumor Immune Microenvironment and Clinical Outcomes in Lung Cancer: A Prospective Cohort Study Objective: This prospective study aims to investigate the causal re...
Detailed Description
1. Background support Sleep disorders are common in patients with lung cancer, and the incidence is as high as 52.6%-70%, which is related to tumor progression and immunosuppression. Animal experiment...
Eligibility Criteria
Inclusion
- Patients with newly diagnosed stage III-IV non-small-cell lung cancer (NSCLC) not receiving systemic therapy (chemotherapy, immunotherapy, or radiotherapy)
Exclusion
- Patients with severe mental illness, other malignant tumors, or receiving sleep medication
Key Trial Info
Start Date :
May 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2028
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT06941948
Start Date
May 1 2025
End Date
January 1 2028
Last Update
April 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhong Shan hospital
Shanghai, China